CFTR and cystic fibrosis: In 2022, Mainz et al. published the first study assessing the impact of the novel triple CFTR modulating therapy with elexacaftor–tezacaftor–ivacaftor (ETI) on GI symptoms captured with the CFAbd-Score 3.0, the only CF-specific GI PROM developed and validated following FDA guidelines [60].